.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, people with metastatic intestinal lumps that obtained biomarker-matched treatments based on circulating cyst DNA profiling revealed a better professional perk than those getting incomparable treatment.